FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Geneviève Plu-Bureau

Research Profile

Procedures

Concepts & Ideas

Chemicals & Drugs

Disorders

Physiology

Postmenopause

Geographic Areas

France

Co-author Network

Publications

TOP 3
Geneviève Plu-Bureau; Justine Hugon-Rodin; Lorraine Maitrot-Mantelet; Marianne Canonico
Hormonal contraceptives and arterial disease: an epidemiological update.
Geneviève Plu-Bureau; Justine Hugon-Rodin; Lorraine Maitrot-Mantelet; Marianne Canonico
Hormonal contraceptives and venous thromboembolism: an epidemiological update.
Pierre Gourdy; Anne Bachelot; Sophie Catteau-Jonard; Nathalie Chabbert-Buffet; Sophie Christin-Maître; Jacqueline Conard; alexandre fredenrich; Anne Gompel; Françoise Lamiche-Lorenzini; Caroline Moreau; Geneviève Plu-Bureau; Anne Vambergue; Bruno Vergès; Véronique Kerlan
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Geneviève Plu-Bureau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Geneviève Plu-Bureau; Justine Hugon-Rodin; Lorraine Maitrot-Mantelet; Marianne Canonico
Hormonal contraceptives and arterial disease: an epidemiological update.
Best practice & research. Clinical endocrinology & metabolism 2013;27(1):35-45.
2013: Geneviève Plu-Bureau; Justine Hugon-Rodin; Lorraine Maitrot-Mantelet; Marianne Canonico
Hormonal contraceptives and venous thromboembolism: an epidemiological update.
Best practice & research. Clinical endocrinology & metabolism 2013;27(1):25-34.
2012: Pierre Gourdy; Anne Bachelot; Sophie Catteau-Jonard; Nathalie Chabbert-Buffet; Sophie Christin-Maître; Jacqueline Conard; alexandre fredenrich; Anne Gompel; Françoise Lamiche-Lorenzini; Caroline Moreau; Geneviève Plu-Bureau; Anne Vambergue; Bruno Vergès; Véronique Kerlan
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology.
Annales d'endocrinologie 2012;73(5):469-87.
2012: Anne Bachelot; Yasmina Badachi; Zeina Chakhtoura; Beny Charbit; Mathieu Coudert; Christiane Coussieu; Jérome Dulon; Geneviève Plu-Bureau; Philippe Touraine
Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia.
European journal of endocrinology / European Federation of Endocrine Societies 2012;167(4):499-505.
2012: Valérie Scarabin-Carré; Séverine Trabado; Sylvie Brailly-Tabard; Marianne Canonico; Pierre Ducimetière; Maurice Giroud; Anne Guiochon-Mantel; Catherine Helmer; Geneviève Plu-Bureau; Joanne Ryan; Pierre-Yves Scarabin
High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study.
Journal of the American Heart Association 2012;1(3):e001388.
2012: C Duflos; Geneviève Plu-Bureau; Elisabeth Thibaud; Frédérique Kuttenn
Breast diseases in adolescents.
Endocrine development 2012;22():208-21.
2011: Marianne Canonico; Geneviève Plu-Bureau; Pierre-Yves Scarabin
Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
Maturitas 2011;70(4):354-60.
2011: Christine Rousset-Jablonski; Marco Alifano; Sophie Camilleri-Broet; Geneviève Plu-Bureau; Jean-François Regnard; Pascal Rousset; Anne Gompel
Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors.
Human reproduction (Oxford, England) 2011;26(9):2322-9.
2011: Valérie Olié; Geneviève Plu-Bureau; Marianne Canonico; Jacqueline Conard; Marie-Hélène Horellou; Pierre-Yves Scarabin
Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
Menopause (New York, N.Y.) 2011;18(5):488-93.
2011: Zeina Chakhtoura; Marianne Canonico; Anne Gompel; Pierre-Yves Scarabin; Geneviève Plu-Bureau
Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis.
The Journal of clinical endocrinology and metabolism 2011;96(4):1169-74.
2011: Valérie Olié; Geneviève Plu-Bureau; Marianne Canonico; Pierre-Yves Scarabin
Risk assessment for recurrent venous thrombosis.
Lancet 2011;377(9771):1072; author reply 1073-4.
2010: Marianne Canonico; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Valérie Olié; Pierre-Yves Scarabin
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.
Menopause (New York, N.Y.) 2010;17(6):1122-7.
2010: Geneviève Plu-Bureau
[A French exception. Transdermal postmenopausal hormone therapy].
La Revue du praticien 2010;60(8):1122-3, 1125-30.
2010: Marianne Canonico; Agnès Fournier; Laure Carcaillon; Valérie Olié; Geneviève Plu-Bureau; Emmanuel Oger; Sylvie Mesrine; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Pierre-Yves Scarabin
Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(2):340-5.
2010: Marianne Canonico; Geneviève Plu-Bureau; Pierre-Yves Scarabin
Lung cancer and hormone replacement therapy.
Lancet 2010;375(9709):117; author reply 118-9.
2009: Zeina Chakhtoura; Marianne Canonico; Anne Gompel; Jean-Christophe Thalabard; Pierre-Yves Scarabin; Geneviève Plu-Bureau
Progestogen-only contraceptives and the risk of stroke: a meta-analysis.
Stroke; a journal of cerebral circulation 2009;40(4):1059-62.
2009: Sandra Dupouy; Véronique Viardot-Foucault; Marco Alifano; Frédérique Souazé; Geneviève Plu-Bureau; Marc Chaouat; Anne Lavaur; Danielle Hugol; Christian Gespach; anne Gompel; Patricia Forgez
The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression.
PloS one 2009;4(1):e4223.
2008: Marianne Canonico; Geneviève Plu-Bureau; Gordon D O Lowe; Pierre-Yves Scarabin
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis.
BMJ (Clinical research ed.) 2008;336(7655):1227-31.
2008: C Pichard; Geneviève Plu-Bureau; M Neves-E Castro; anne Gompel
Insulin resistance, obesity and breast cancer risk.
Maturitas 2008;60(1):19-30.
2008: Claire Bricaire; Geneviève Plu-Bureau
[Difficult contraceptions].
La Revue du praticien 2008;58(1):55-64.
2007: anne Gompel; Geneviève Plu-Bureau
Ovarian cancer and hormone replacement therapy.
Lancet 2007;370(9591):932; author reply 932-3.
2007: Anne Bachelot; Kathleen Laborde; Jean-Louis Bresson; Geneviève Plu-Bureau; A Raynaud; X Bertagna; Agnès Mogenet; M Mansour; V Lucas-Jouy; J-P Gayno; Yves Reznik; Jean-Marc Kuhn; L Billaud; MC Vacher-Lavenu; M Putterman; Irène Mowszowicz; Philippe Touraine; Frédérique Kuttenn
Luteinizing hormone pulsatility in patients with major ovarian hyperandrogenism.
Journal of endocrinological investigation 2007;30(8):636-46.
2007: Regine Sitruk-Ware; Geneviève Plu-Bureau; Joël Menard; Jacqueline Conard; Sushma Kumar; Jean-Christophe Thalabard; Barbara Tokay; Philippe Bouchard
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.
The Journal of clinical endocrinology and metabolism 2007;92(6):2074-9.
2007: Marianne Canonico; Emmanuel Oger; Geneviève Plu-Bureau; Jacqueline Conard; Guy Meyer; Hervé Lévesque; Nathalie Trillot; Marie-Thérèse Barrellier; Denis Wahl; Joseph Emmerich; Pierre-Yves Scarabin
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study.
Circulation 2007;115(7):840-5.
2007: Anne Bachelot; Geneviève Plu-Bureau; Elisabeth Thibaud; Kathleen Laborde; Graziella Pinto; Dinane Samara; Claire Nihoul-Fékété; Frédérique Kuttenn; Michel Polak; Philippe Touraine
Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Hormone research 2007;67(6):268-76.
2006: Marianne Canonico; Céline Straczek; Emmanuel Oger; Geneviève Plu-Bureau; Pierre-Yves Scarabin
Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings.
Maturitas 2006;54(4):372-9.
2006: Geneviève Plu-Bureau; Monique G Lê; Regine Sitruk-Ware; Jean-Christophe Thalabard
Cyclical mastalgia and breast cancer risk: results of a French cohort study.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(6):1229-31.
2005: Céline Straczek; Emmanuel Oger; Marianne Beau Yon de Jonage-Canonico; Geneviève Plu-Bureau; Jacqueline Conard; Guy Meyer; Martine Alhenc-Gelas; Hervé Lévesque; Nathalie Trillot; Marie-Thérèse Barrellier; Denis Wahl; Joseph Emmerich; Pierre-Yves Scarabin
Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.
Circulation 2005;112(22):3495-500.
2005: Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Benign breast diseases.
Journal of mammary gland biology and neoplasia 2005;10(4):325-35.
2005: Pierre-Yves Scarabin; Emmanuel Oger; Tabassome Simon; Geneviève Plu-Bureau
Estrogen plus progestin and risk of venous thrombosis.
JAMA : the journal of the American Medical Association 2005;293(11):1322; author reply 1322-3.
2004: Jacqueline Conard; Geneviève Plu-Bureau; Narges Bahi; Marie-Hélène Horellou; Clara Pelissier; Jean-Christophe Thalabard
Progestogen-only contraception in women at high risk of venous thromboembolism.
Contraception 2004;70(6):437-41.
2004: Regine Sitruk-Ware; Geneviève Plu-Bureau
Exogenous progestagens and the human breast.
Maturitas 2004;49(1):58-66.
2004: Martine Alhenc-Gelas; Geneviève Plu-Bureau; S Guillonneau; Jean Michel Kirzin; Martine Aiach; N Ochat; Pierre-Yves Scarabin
Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives.
Journal of thrombosis and haemostasis : JTH 2004;2(9):1594-600.
2004: Delphine Lévy; Geneviève Plu-Bureau; Yves Decroix; Danielle Hugol; William Rostène; Adi Kimchi; anne Gompel
Death-associated protein kinase loss of expression is a new marker for breast cancer prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):3124-30.
2004: M Algazi; Geneviève Plu-Bureau; A Flahault; M-G Dondon; Monique G Lê
[Could treatments with beta-blockers be associated with a reduction in cancer risk?].
Revue d'épidémiologie et de santé publique 2004;52(1):53-65.
2004: C Duflos; Geneviève Plu-Bureau; Elisabeth Thibaud; Frédérique Kuttenn
Breast diseases in adolescents.
Endocrine development 2004;7():183-96.
2003: Meyer M Samama; Roberto A Rached; Marie-Hélène Horellou; Sandro Aquilanti; Valérie G Mathieux; Geneviève Plu-Bureau; Ismail Elalamy; Jacqueline Conard
Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone.
British journal of haematology 2003;123(2):327-34.
2003: Pierre-Yves Scarabin; Emmanuel Oger; Geneviève Plu-Bureau
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk.
Lancet 2003;362(9382):428-32.
2003: Grégoire LE GAL; Véronique Gourlet; Patricia Hogrel; Geneviève Plu-Bureau; Pierre Jean Touboul; Pierre-Yves Scarabin
Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study.
Atherosclerosis 2003;166(1):163-70.
2002: Geneviève Plu-Bureau; Jean-Christophe Thalabard
[It is not advisable to prescribe hormonal replacement therapy to a woman with proliferative mastopathy with atypia].
Gynécologie, obstétrique & fertilité 2002;30(4):335-9.
2001: V Marque; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Emmanuel Oger; Pierre-Yves Scarabin
The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women.
Thrombosis and haemostasis 2001;86(2):713-4.
2001: Philippe Touraine; Geneviève Plu-Bureau; N Beressi; P Decq; Jean-Christophe Thalabard; Frédérique Kuttenn
Resumption of luteinizing hormone pulsatility and hypogonadotropic hypogonadism after endoscopic ventriculocisternostomy in a hydrocephalic patient.
Fertility and sterility 2001;76(2):390-3.
2001: Philippe Touraine; Geneviève Plu-Bureau; C Beji; Pierre Mauvais-Jarvis; Frédérique Kuttenn
Long-term follow-up of 246 hyperprolactinemic patients.
Acta obstetricia et gynecologica Scandinavica 2001;80(2):162-8.
2001: Emmanuel Oger; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Louise Mennen; M Cambillau; L Guize; Y Pujol; Pierre-Yves Scarabin
Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users.
Thrombosis research 2001;101(2):35-43.
2000: Emmanuel Oger; Martine Alhenc-Gelas; Geneviève Plu-Bureau; L Guize; Pierre-Yves Scarabin
Plasma 17beta estradiol is inversely correlated with circulating vascular cell adhesion molecule.
Thrombosis and haemostasis 2000;84(6):1125.
2000: M O Bernier; Geneviève Plu-Bureau; N Bossard; L Ayzac; Jean-Christophe Thalabard
Breastfeeding and risk of breast cancer: a metaanalysis of published studies.
Human reproduction update 2000;6(4):374-86.
2000: Geneviève Plu-Bureau; N Bossard; Jean-Christophe Thalabard
[Oral contraception and genetic factors in breast cancer: characteristics and limits of case-only studies].
Revue d'épidémiologie et de santé publique 2000;48(3):294-303.
1999: Regine Sitruk-Ware; Geneviève Plu-Bureau
Progestins and cancer.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1999;13 Suppl 4():3-9.
1999: Pierre-Yves Scarabin; Martine Alhenc-Gelas; Emmanuel Oger; Geneviève Plu-Bureau
Hormone replacement therapy and circulating ICAM-1 in postmenopausal women--a randomised controlled trial.
Thrombosis and haemostasis 1999;81(5):673-5.
1999: Geneviève Plu-Bureau; Monique G Lê; Jean-Christophe Thalabard; Regine Sitruk-Ware; Pierre Mauvais-Jarvis
Percutaneous progesterone use and risk of breast cancer: results from a French cohort study of premenopausal women with benign breast disease.
Cancer detection and prevention 1999;23(4):290-6.
1998: Philippe Touraine; C Deneux; Geneviève Plu-Bureau; Pierre Mauvais-Jarvis; Frédérique Kuttenn
Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia.
Journal of endocrinological investigation 1998;21(11):732-6.
1998: Geneviève Plu-Bureau; Jean-Christophe Thalabard
[Hereditary risks of breast cancer. Interaction of genetic factors and hormonal factors].
Annales d'endocrinologie 1998;59(6):465-9.
1997: Pierre-Yves Scarabin; Martine Alhenc-Gelas; Geneviève Plu-Bureau; P Taisne; R Agher; M Aiach
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):3071-8.
1997: Geneviève Plu-Bureau; Monique G Lê
[Oral contraception and the risk of breast cancer].
Contraception, fertilité, sexualité (1992) 1997;25(4):301-5.
1996: Geneviève Plu-Bureau; J Amiral; L Guize; Pierre-Yves Scarabin
Safety of combined oral contraceptive pills.
Lancet 1996;347(9000):549.
1996: Pierre-Yves Scarabin; E Billaud; Geneviève Plu-Bureau; R Agher
HRT and ACE activity in postmenopausal women.
Lancet 1996;347(8994):122.
1995: Pierre-Yves Scarabin; Geneviève Plu-Bureau; D Zitoun; Lucienne Bara; L Guize; M M Samama
Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Thrombosis and haemostasis 1995;74(3):928-32.
1995: Monique G Lê; Geneviève Plu-Bureau
[Women at high risk for breast cancer: can we define a group of women in France who could participate in a prevention trial?].
Contraception, fertilité, sexualité (1992) 1995;23(3):199-202.
1994: Geneviève Plu-Bureau; Monique G Lê; Regine Sitruk-Ware; Jean-Christophe Thalabard; Pierre Mauvais-Jarvis
Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.
British journal of cancer 1994;70(2):270-7.
1993: Geneviève Plu-Bureau; D Bureau; Jean-Christophe Thalabard
[Socioeconomic stakes of menopause: evaluation of the cost-effectiveness studies].
La Revue du praticien 1993;43(20):2665-9.
1993: Pierre-Yves Scarabin; Geneviève Plu-Bureau; Lucienne Bara; C Bonithon-Kopp; L Guize; M M Samama
Haemostatic variables and menopausal status: influence of hormone replacement therapy.
Thrombosis and haemostasis 1993;70(4):584-7.
1993: Geneviève Plu-Bureau; Pierre-Yves Scarabin; Lucienne Bara; A Malmejac; L Guize; M Samama
Factor VII activation and oral contraceptives.
Thrombosis research 1993;70(3):275-80.
1993: I Charreau; Geneviève Plu-Bureau; A Bachelot; Genevieve Contesso; J M Guinebretiére; Monique G Lê
Oral contraceptive use and risk of benign breast disease in a French case-control study of young women.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1993;2(2):147-54.
1993: Pierre-Yves Scarabin; Geneviève Plu-Bureau
[Quantitative evaluation of the cardiovascular risk associated with hormone substitution therapy during menopause].
Archives des maladies du coeur et des vaisseaux 1993;86(2):243-8.
1992: Geneviève Plu-Bureau; Jean-Christophe Thalabard; Regine Sitruk-Ware; B Asselain; Pierre Mauvais-Jarvis
Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case-control study among French women.
British journal of cancer 1992;65(6):945-9.
1989: Jean-Christophe Thalabard; Geneviève Plu-Bureau; B Falissard
A program running under MS-DOS for the analysis of epidemiologic stratified or matched data.
Computer methods and programs in biomedicine 1989;28(3):191-3.